Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Under the terms of the Rights Offering, the holders of XOMA’s common stock and Series X Preferred Stock and Series Y Preferred Stock as of 5:00 p.m., New York time, on November 29, 2019, the record date for the Rights Offering, are entitled to purchase up to 1,000,000 shares of common stock in the aggregate at a subscription price equal to $22.00 per share, or under certain circumstances, shares of non-voting Series Z preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated December 2, 2019, relating to the Rights Offering.

As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. Novartis dedicated eight (8) slides to the iscalimab update. Please find the Novartis R&D Day Presentation on the Novartis website (slide numbers 1, 2, 64-71).

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Today is shaping up negative for XOMA Corporation (NASDAQ:XOMA) shareholders, with the analysts delivering a...

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

At the closing, XOMA sold and issued an aggregate of 626,805 shares of its common stock (the “Common Stock”) pursuant to the exercise of subscriptions in the Rights Offering from its existing stockholders. In addition, BVF Partners L.P., a stockholder of the Company, purchased an additional 373,195 shares of Common Stock pursuant to the exercise of its oversubscription rights. Combined, the Company sold and issued an aggregate of 1,000,000 shares of Common Stock for aggregate gross proceeds of $22 million.

Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation (XOMA) today announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody. As part of the agreement, Zydus will advance the new IO candidate through formal clinical trials. Zydus has been granted exclusive rights to develop and commercialize the therapy in India, Brazil, Mexico and other emerging markets, and XOMA has the potential to receive single-to double-digit royalties on commercial sales in those territories.

EMERYVILLE, Calif., May 05, 2020 -- XOMA Corporation (Nasdaq: XOMA) reported its first quarter 2020 financial results and provided a COVID-19 business update. “Our first.

EMERYVILLE, Calif., Nov. 05, 2019 -- XOMA Corporation (Nasdaq: XOMA) today reported its third quarter 2019 financial results.  “XOMA’s portfolio of future potential royalty-.

As of late, it has definitely been a great time to be an investor in XOMA.

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings.

It certainly might concern XOMA Corporation (NASDAQ:XOMA) shareholders to see the share price down 33% in just 30...

Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Rights Offering will be available to all shareholders of record on November 29, 2019$22 million to be raised; fully backstopped EMERYVILLE, Calif., Nov. 19, 2019 -- XOMA.

Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments Received $15.8 million from partners during the year Current cash.

The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

If you own shares in XOMA Corporation (NASDAQ:XOMA) then it's worth thinking about how it contributes to the...